Pfizer Inc. News
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
see morePfizer Inc. Market News
15d
Pfizer’s Tilrekimig Delivers Strong Phase 2 Atopic Dermatitis Data, Supporting Pipeline Momentum
- Pfizer’s experimental atopic dermatitis drug Tilrekimig achieved significant skin clearance in a Phase 2 study, marking a notable development for its biopharma pipeline.
29d
Pfizer Shares Slip Amidging Investor Interest in SCD Pipeline Uncertainty
Pfizer (PFE) shares edged lower amid renewed scrutiny over its sickle cell disease portfolio, as prospects dim for Oxbryta and inclacumab.
21 Sep at 09:18
Pfizer’s XFG‑Adapted COVID‑19 Vaccine Wins FDA Approval, Sets Stage for Upcoming Season
Pfizer’s updated COVID‑19 vaccine targeting the XFG variant has secured FDA approval as of August 27, 2026, positioning the company for immediate seasonal rollout.
07 Sep at 09:17
No New Material Developments for Pfizer’s PFE Stock in the Past Week
No major verified developments directly impacting Pfizer’s (PFE) stock have occurred in the past week in biopharma discovery, development, manufacturing or marketing.
24 Aug at 09:17
Pfizer Gains Regulatory Green Light in Europe for Lyme Disease Vaccine Filing
Pfizer’s marketing application for its Lyme disease vaccine candidate was validated by the EMA on August 14, enabling a formal review process in Europe.